Nonlinear Cites ‘Diverged’ Proteomics Priorities for Amersham Split
In a statement released last week following the announcement that GeneBio had supplanted Nonlinear Dynamics as the supplier for Amersham Biosciences’ 2D gel software [BioInform 07-21-03], Nonlinear CEO Will Dracup claimed that “Nonlinear and Amersham Biosciences’ priorities within proteomics have diverged over the past two years. We therefore felt it was no longer in our best interests to be represented by them within this market.”
Nonlinear and Amersham held an OEM agreement since 1996, when Nonlinear was chosen as Amersham Biosciences’ supplier of 1D and 2D gel analysis software, distributed under the ImageMaster brand. An extended agreement in 2001 added Nonlinear’s Progenesis product line, distributed under the Ettan brand. The agreements have now expired and Nonlinear said it has opted not to renew.
Dracup told BioInform’s sister publication ProteoMonitor that, unlike GeneBio, Nonlinear was not willing to grant Amersham an exclusive license to its software. “Everyone would love to have an exclusive license with Nonlinear,” he said, noting that the company has eight 2D gel analysis products, compared to GeneBio’s one. “We are not willing to do that.”
An exclusive contract would have been undesirable for a number of reasons, according to Dracup, including product development. “If you only have one customer that you supply to, it’s very difficult to keep your products refreshed in the marketplace and to reinvest money,” he told ProteoMonitor.
Iobion Licenses Affy APIs
Gene expression analysis software firm Iobion said last week that it has licensed Affymetrix’s application programming interfaces for its GeneChip file data.
Iobion said it has incorporated the file APIs into its GeneTraffic and ArrayAssist microarray analysis products.
UK’s BBSRC Launches Phase II of Bioinformatics Grid Program
The UK’s Biotechnology and Biological Sciences Research Council last week entered the second phase of its “Bioinformatics and e-Science Program,” which initially launched in May 2001.
The BBSRC is accepting applications through October 10, 2003 for projects that “move toward the development of Grid applications for science across BBSRC’s remit, but, in particular, proteomics, integrative biology, genomics, dynamic cellular processes, protein structure, and biodiversity.”
Funding of approximately £14 million ($22.6 million) will be available for the program over the next three years.
Additional information is available at: www.bbsrc.ac.uk/science/initiatives/bep2.html.
Celera’s Q2 Info Business Revenues Fall
The Celera Genomics Group of Applera last week reported revenues of $21.5 million for the quarter ended June 30, 2003, compared to $28.1 million for the year-ago quarter.
Online/Information Business revenue was $17.2 million for the company’s fourth fiscal quarter, compared to $19.8 million in the same period last year. Operating income for the Online/Information Business was $6.2 million compared to $6.8 million in the prior year period.
R&D expenses also dropped, to $28.5 million, compared to $36.7 million for the fourth quarter of 2002.
Celera’s quarterly net loss narrowed slightly, to $19.4 million, compared to a net loss of $28.8 million for the same period last year.
The company’s revenue for fiscal 2003 fell to $88.3 million, compared to $120.9 million in the prior year. Celera attributed the drop to its decision not to pursue additional sequencing service business. The company anticipates that its revenues will continue to fall, to $55-$60 million for fiscal year 2004, in part because “a number of Online/Information Business agreements are expected to expire during fiscal 2004.”
At the end of June, Celera had $802.4 million in cash and short-term investments.
Compugen Reports Flat Q2 Revenues
Compugen last week posted nearly flat revenues for the second quarter, amid slightly narrowed net losses.
The company’s revenues for the second quarter ended June 30, 2003, were $2.9 million, compared to $2.8 million for the second quarter of 2002.
Compugen’s R&D expenses were up slightly, to $3.4 million, from $3.0 million for the year-ago quarter.
The company’s net losses came to $2.4 million, compared to $2.8 million for Q2 02.
As of June 30, the company had $34.8 million in cash, cash equivalents, short-term cash deposits, and marketable securities.
EPO Licenses Lion’s SRS for Patent Searching
Lion Bioscience said it has signed an agreement with the European Patent Office for its SRS software and related professional services.
The EPO will use SRS to conduct prior art searches in the patent approval process at its sites in Munich, the Hague, Berlin, and Vienna.
Tripos Posts Q2 Profit
Tripos last week reported a 14 percent increase in revenues for the second quarter ended June 30, which contributed to a net income of $600,000 for the quarter.
The company posted Q2 revenues of $12.6 million, compared to $11.1 million in the year-ago period.
Net income of $600,000 for the quarter compared with a net loss of $1.3 million for the second quarter of 2002.
R&D spending increased from $2.7 million in Q2 2002 to $3.9 million in Q2 03.
As of June 30, 2003, Tripos had $7.2 million in cash and cash equivalents.
The company said it plans to release up to eight additional software offerings this year, but declined to provide guidance on its expected profitability from operations for the year.
VizX Plans to be Cash-Flow Positive by Year End
Privately held gene expression software company VizX Labs intends to be cash-flow positive at the end of the year, according to an announcement from CEO and co-founder Thomas Ranken.
“We will develop the capacity to expand our company from new funding sources: earnings, investment, and debt,” said Ranken.
Ranken said that direct sales of the company’s GeneSifter.net web-based software are increasing 23 percent per month.
The company has funded over 60 percent of its convertible-note financing and is seeking additional investors “to complete the financing this quarter,” Ranken said.